Cite
HARVARD Citation
Armoiry, X. et al. (2021). Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England: a review comparing the assessment by HAS and NICE. Expert opinion on biological therapy. pp. 741-747. [Online].